HIV and HCV therapies in 2016: Optimal regimens

AIDS Reviews

Volumn 18, Issue 4, 2016, Pages 212-221

  Sasadeusz, Joe ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Coinfection; DAA; Drug drug interaction; Hepatitis C; HIV; Therapy

Indexed keywords

ANTIVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ZIDOVUDINE;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INSOMNIA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTON; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VIRUS LOAD; COMPLICATION; HEPATITIS C; HIV INFECTIONS;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 85007318343     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. U.S. Department of Health and Human Services. Panel on Guidelines for Adults and Adolescents. Updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. April 8, 2015.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107-15.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345:41-52.
4. Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(Suppl 1):S93-8.
5. WHO. Progress report 2011: Global HIV/AIDS response. WHO, 2011.
6. Sherman KE, Thomas D, Chung RT. Human immunodeficiency virus and liver disease forum 2012. Hepatology. 2014;59:307-17.
7. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284: 450-6.
8. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS. 1995;9:1131-6.
9. Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis. 1998;177:1480-8.
10. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-8.
11. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562-9.
12. van der Helm J, Geskus R, Sabin C, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. 2013;144:751-60.
13. Lo Re V, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160:369-79.
14. Worm SW, Bower M, Reiss P, et al. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013;13:471.
15. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012;55:728-36.
16. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-13.
17. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47-55.
18. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410-25.
19. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
20. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-50.
21. Chung R, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons. N Engl J Med. 2004;351:451-9.
22. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292: 2839-48.
23. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22-31.
24. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIVinfected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972-82.
25. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis. 2005;40(Suppl 5):S349-54.
26. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov. 2013;12:595-610.
27. Rong L, Ribeiro RM, Perelson AS. Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol. 2012;74:1789-817.
28. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159:86-96.
29. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13:597-605.
30. Dieterich D, Rockstroh JK, Orkin C, et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis. 2014;59:1579-87.
31. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098-106.
32. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353-61.
33. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-in-fected with HIV-1: a randomized trial. JAMA. 2015;313:1223-31.
34. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373:705-13.
35. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373:714-25.
36. Gandhi Y, Adamczyk R, Wang R, et al. Assessment of drug-drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ritonavir. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC. 2015.
37. Rockstroh, JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-27.
38. Wyles D, Brau N, Kottilil S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the Phase 3 ASTRAL-study. International Liver Congress, Barcelona, abstract PS104, 2016.
39. Milazzo L, Lai A, Calvi E, et al Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med. 2016. [Epub ahead of print].
40. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24:1799-812.
41. Mahony AA, Donnan EJ, Lester RA, et al. Beyond injecting drug use: investigation of a Victorian cluster of hepatitis C among HIV-infected men who have sex with men. Med J Aust. 2013;198:210-4.
42. Boesecke C, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS. 2011;6:278-84.
43. Fierer DS, Dieterich DT, Mullen MP, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014;58:873-9.
44. Matinello M, Gane E, Hellard M et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. Hepatology. 2016. [Epub ahead of print].
45. Terrault NA, Roland ME, Schiano T, et al, Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716-26.
46. Grant J, Hawkins C, Brooks H, et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS. 2016;30:93-8.
47. Campos-Varela I, Moreno A, Morbey A, et al. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy. Aliment Pharmacol Ther. 2016;43: 1319-29.
48. Miro JM, Stock P, Teicher E, et al. Outcome and management of HCV/ HIV coinfection pre-and post-liver transplantation. A 2015 update. J Hepatol. 2015;62:701-11.
49. Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11: 333-41.
50. HIV I Chart and HEP I Chart. Available at: http://www.hep-druginteractions.org.